EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Genzyme Rival Gets FDA Nod

Protalix BioTherapeutics, an Israel-based biotech company, said today it has received FDA approval for a treatment protocol of its experimental drug for Gaucher’s disease, which will allow patients to get expanded access to the drug during a shortage of the leading therapy, Genzyme’s imiglucerase (Cerezyme). Shares of Protalix (AMEX: PLX) climbed 10 percent in mid-day trading on the news.